Related Experiment Videos
Alpha CD 2 mAb treatment safely attenuates adoptive transfer colitis
Nina N Pawlowski1, Hacer Kakirman, Anja A Kühl
1Medizinische Klinik I, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Summary
CD2 directed immunotherapy shows promise in preventing and treating inflammatory bowel disease (IBD) by modulating T cell responses. This approach effectively reduced colitis severity and maintained parasite control in preclinical models.
Area of Science:
- Immunology
- Gastroenterology
- Therapeutic Development
Background:
- T lymphocyte dysfunction, including increased proliferation, impaired apoptosis, and cytokine dysregulation, is implicated in inflammatory bowel disease (IBD) pathogenesis.
- Alpha CD2 monoclonal antibody (mAb) has demonstrated potential in correcting these T cell abnormalities.
Purpose of the Study:
- To investigate the efficacy of CD2-directed immunotherapy in preventing and ameliorating adoptive transfer colitis.
- To assess the safety and underlying mechanisms of CD2-directed immunotherapy in preclinical colitis models.
Main Methods:
- Adoptive transfer colitis models were established using CD4(+) T cell blasts in RAG 1(-/-) mice or CD45RB(high) CD4(+) T cells in SCID mice.
- Mice were treated with alpha CD2 mAb or control IgG, initiating treatment either at cell transfer or upon disease onset.
- Disease activity was evaluated through clinical monitoring, microscopic scoring, endoscopy, and blood analysis; cytokine production and T cell proliferation were measured.
Main Results:
- Alpha CD2 mAb significantly improved survival in the T-cell blast transfer model when administered prophylactically (69% vs 0% survival).
- Prophylactic treatment with alpha CD2 mAb delayed disease onset and reduced severity in the SCID colitis model.
- While less effective in established colitis, alpha CD2 mAb combined with dexamethasone showed a survival benefit compared to dexamethasone alone; prophylactic treatment reduced IL-2 secretion and T cell proliferation without impairing anti-parasitic immunity.
Conclusions:
- CD2-directed immunotherapy can attenuate, delay, or ameliorate adoptive transfer colitis, likely through inhibition of IL-2 secretion and T cell proliferation.
- This therapeutic strategy demonstrates potential for managing IBD while preserving essential immune responses, such as defense against Toxoplasma gondii infection.